Latest News for: st2
Edit
Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
PR Newswire 11 Feb 2026
(9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications.
Edit
Earnings Release PDF Navy .st0{fill:none;} .st1{fill:#003C71;} .st2{fill:#FFFFFF;} .st3{fill-rule:evenodd;clip-rule:evenodd;fill:#003C71;} Q4 2025 (UnitedHealth Group Inc)
Public Technologies 27 Jan 2026
). UnitedHealth Group Reports 2025 Results and Issues 2026 Outlook. Full Year 2025 Revenues of $447.6 Billion Grew 12% Year-Over-Year; Earnings of $13.23 Per Share; Adjusted Earnings of $16.35 Per Share. Full Year 2026 Revenue Outlook Greater Than ... $442.
Edit
Constitutively high levels of endogenous soluble ST2 inhibit food allergic responses in mice
PNAS 05 Jan 2026
Edit
Watauga Democrat
25 Dec 2025
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
Watauga Democrat
25 Dec 2025
Edit
SOKO HELIKOPTERI d.d. Mostar - Presegmentation to the Free Stock Market - ST2 (Soko Helikopteri dd Mostar)
Public Technologies 16 Dec 2025
The listed issuer will be traded on the subsegment of the Free Market ST2 from 16.12.2025.
Edit
Annualized Severe COPD Exacerbation Rate Reduced by Over 40%: Mabwell Announces Phase IIa Results for Innovative Anti-ST2 Antibody 9MW1911
PR Newswire 01 Dec 2025
9MW1911 is an innovative anti-ST2 antibody developed using Mabwell's high-efficiency B-cell screening platform.
- 1
